Phase II trial of sorafenib in advanced thyroid cancer.
暂无分享,去创建一个
Andrea B Troxel | Keith T Flaherty | K. Flaherty | A. Troxel | S. Mandel | P. O'dwyer | M. Brose | L. Loevner | Peter J O'Dwyer | Laurie A Loevner | Marcia S Brose | Susan J Mandel | M. Redlinger | V. Gupta-Abramson | A. Nellore | K. Puttaswamy | K. Ransone | Vandana Gupta-Abramson | Anoma Nellore | Kanchan Puttaswamy | Maryann Redlinger | Kathy Ransone
[1] E. Vokes,et al. A phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers , 2007 .
[2] N. Aaronson,et al. Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Kyung-Hee Kim,et al. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. , 2004, Yonsei medical journal.
[4] Mark J Ratain,et al. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Mithat Gonen,et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. , 2006, The Journal of clinical endocrinology and metabolism.
[6] J. Shah,et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. , 2003, Journal of the American College of Surgeons.
[7] M. Saji,et al. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. , 2002, Thyroid : official journal of the American Thyroid Association.
[8] M. Fleisher,et al. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. , 2002, The Journal of clinical endocrinology and metabolism.
[9] J. Schiller,et al. Angiogenesis inhibitors in the treatment of lung cancer. , 2007, Critical reviews in oncology/hematology.
[10] H. Namba,et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. , 2003, The Journal of clinical endocrinology and metabolism.
[11] M. Xing,et al. BRAF mutation in thyroid cancer. , 2005, Endocrine-related cancer.
[12] D. Fraker,et al. Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma , 2007 .
[13] J. Desai,et al. Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors , 2006, Annals of Internal Medicine.
[14] Y. Nikiforov,et al. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. , 2007, Endocrinology.
[15] E. Bergstralh,et al. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. , 1988, The Journal of clinical endocrinology and metabolism.
[16] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[17] M. Ratain,et al. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] P. Ladenson,et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. , 2005, The Journal of clinical endocrinology and metabolism.
[19] Q. Duh,et al. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients. , 1999, Surgery.
[20] J. Heverhagen,et al. Significant clinical and biologic activity of RAF/VEGF-R kinase inhibitor BAY 43-9006 in patients with metastatic papillary thyroid carcinoma (PTC): Updated results of a phase II study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] C. Hill,et al. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. , 1974, The New England journal of medicine.
[22] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[23] D. Schoenfeld,et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma , 1985, Cancer.
[24] M. Nikiforova,et al. Prevalence of RET/PTC Rearrangements in Hashimoto's Thyroiditis and Papillary Thyroid Carcinomas , 2002, International journal of surgical pathology.
[25] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[26] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[27] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[28] M. Feldman,et al. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). , 2006, The American journal of pathology.
[29] A. Jemal,et al. Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.
[30] D. Pfister,et al. Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label phase II trial , 2007 .
[31] P. Ladenson,et al. BRAF mutation in papillary thyroid carcinoma. , 2003, Journal of the National Cancer Institute.
[32] L. Bastholt,et al. Initial results from a phase II trial of motesanib diphosphate (AMG 706) in patients with differentiated thyroid cancer (DTC) , 2007 .
[33] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.